Rapid evolution of fluoroquinolone-resistant Escherichia coli in Nigeria is temporally associated with fluoroquinolone use by Lamikanra, Adebayo et al.
RESEARCH ARTICLE Open Access
Rapid evolution of fluoroquinolone-resistant
Escherichia coli in Nigeria is temporally associated
with fluoroquinolone use
Adebayo Lamikanra
1, Jennifer L Crowe
2, Rebeccah S Lijek
2, Babatunde W Odetoyin
3, John Wain
4,
A Oladipo Aboderin
3 and Iruka N Okeke
2*
Abstract
Background: Antibiotic resistance has necessitated fluoroquinolone use but little is known about the selective
forces and resistance trajectory in malaria-endemic settings, where selection from the antimalarial chloroquine for
fluoroquinolone-resistant bacteria has been proposed.
Methods: Antimicrobial resistance was studied in fecal Escherichia coli isolates in a Nigerian community.
Quinolone-resistance determining regions of gyrA and parC were sequenced in nalidixic acid resistant strains and
horizontally-transmitted quinolone-resistance genes were sought by PCR. Antimicrobial prescription practices were
compared with antimicrobial resistance rates over a period spanning three decades.
Results: Before 2005, quinolone resistance was limited to low-level nalixidic acid resistance in fewer than 4% of E.
coli isolates. In 2005, the proportion of isolates demonstrating low-level quinolone resistance due to elevated efflux
increased and high-level quinolone resistance and resistance to the fluoroquinolones appeared. Fluoroquinolone
resistance was attributable to single nucleotide polymorphisms in quinolone target genes gyrA and/or parC.B y
2009, 35 (34.5%) of isolates were quinolone non-susceptible with nine carrying gyrA and parC SNPs and six bearing
identical qnrS1 alleles. The antimalarial chloroquine was heavily used throughout the entire period but E. coli with
quinolone-specific resistance mechanisms were only detected in the final half decade, immediately following the
introduction of the fluoroquinolone antibacterial ciprofloxacin.
Conclusions: Fluoroquinolones, and not chloroquine, appear to be the selective force for fluoroquinolone-resistant
fecal E. coli in this setting. Rapid evolution to resistance following fluoroquinolone introduction points the need to
implement resistant containment strategies when new antibacterials are introduced into resource-poor settings
with high infectious disease burdens.
Keywords: antimicrobial resistance, antimicrobial use, quinolone resistance, drug resistance, ciprofloxacin, fluoroqui-
nolones, selective pressure, Nigeria, chloroquine, antimalarial, fluoroquinolone-resistant, Escherichia coli
1. Background
Chloroquine has been described as one of the most
important drugs ever used to treat an infection. This
cheap and effective drug was the primary antimalarial
worldwide until resistance emerged in the 1970s [1].
Multiple alleles of a chloroquine resistance transporter
gene, pfcrt, and a multidrug resistance transporter gene,
pfmdr1, are associated with chloroquine resistance in
Plasmodium falciparum.R e s i s t a n tP. falciparum haplo-
types that predominate in sub-Saharan Africa appear to
possess a fitness disadvantage, suggesting that they are
maintained by selective pressure from chloroquine,
which is still heavily used [2,3]. Davidson et al [4]
recently proposed that, in addition to the selective pres-
sure for chloroquine-resistant plasmodia, chloroquine’s
weak antibacterial activity confers sufficient selective
advantage for fluoroquinolone resistant Escherichia coli
(FQREC), which emerged in rural Guyana in the
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antimalarial selects for fluoroquinolone-resistant bac-
teria, justification for reintroduction-by combining it
with resistance-reversing chemicals [5] or by withdraw-
ing it until susceptibility is returned and then reintrodu-
cing it in combination with other antimalarials [2]-could
decrease because of the great and growing need for
fluoroquinolones. However, little is known about resis-
tance, drug consumption and selection in malaria-ende-
mic Africa, where high levels of chloroquine and
fluoroquinolone use now occurs concurrently.
The quinolone antibacterial nalidixic acid was origin-
ally derived from a byproduct of chloroquine synthesis
and shares structural features with chloroquine [6]. Nali-
dixic acid and its more active derivatives, the fluoroqui-
nolones, were rarely used in Africa before the late 1990s
because of their high cost. More recently, bacterial resis-
tance to cheaper antibacterials has necessitated wide-
spread fluoroquinolone use. Patents protecting
ciprofloxacin and perfloxacin have recently expired,
allowing for cheaper generics to be disseminated widely.
Fluoroquinolones are stable, orally administrable, and
now affordable. In the last decade, fluoroquinolones
have become first- and second-line antibacterials of
choice for acute respiratory, enteric and urinary tract
infections as well as serious systemic infections such as
bacteremia [7,8]. Fluoroquinolones are also employed in
combination with other antimicrobials to treat multi-
drug resistant tuberculosis [9,10]. Additionally, their use
and misuse in the informal sector, by unsanctioned pro-
viders and through self medication, is commonplace in
Nigeria and in many other parts of Africa [11].
Quinolones inhibit the activity of bacterial DNA gyr-
ase and topoisomerase enzymes, which are essential for
replication [12]. Single nucleotide polymorphisms in the
quinolone resistance determining regions (QRDR) of
gyrA and parC, two of the genes that encode DNA gyr-
ase and topoisomerase IV respectively, can lead to con-
formational changes in these enzymes that prevent
quinolones from binding but still preserve their enzy-
matic function [13]. In E. coli and related Gram-negative
bacteria, DNA gyrase is the first target for fluoroquino-
lones. If gyrA has resistance-conferring mutations, the
primary target of fluoroquinolones switches from DNA
gyrase to topoisomerase IV [12,14,15]. Mutations in the
QRDRs of gyrA and parC are the most commonly docu-
mented quinolone resistance mechanisms, but resistance
i sa l s ok n o w nt ob ec o n f e r r e db ym u t a t i o n si nt h es e c -
ond topoisomerase gene, parE [14]. Quinolone resis-
tance can also be acquired horizontally through
transferable aac(6’)-Ib or quinolone resistance (qnr)
DNA. AAC(6’)-Ib encodes a ciprofloxacin acetylating
enzyme, while the product of qnr inhibits quinolones
binding to target proteins [16,17]. Another mechanism
of quinolone resistance relies on upregulation of efflux
pumps that export quinolones and other antimicrobials
out of the bacterial cell. For example, mutations in the
gene acrR, which encodes a repressor of the acrAB
pump genes, are associated with quinolone resistance
[18] Recently, qepA and oqxAB, which encode horizon-
tally-transmitted efflux pumps have also been described
[17,19].
Low-level resistance to the quinolones often evolves
by acquisition of one resistance-conferring mutation or
gene. Subsequent genetic changes lead to higher levels
of resistance to the first generation quinolone nalidixic
acid and a broadening of the resistance spectrum to
include second-generation quinolones (first generation
fluoroquinolones) such as ciprofloxacin, followed by
newer second- and third-generation fluoroquinolones
that are yet to reach markets in Nigeria and most other
African countries [12,20]. Although multiple mechan-
isms of quinolone resistance have been reported from
other continents, there are very few data from sub-
Saharan Africa on the molecular basis for quinolone
resistance. Prior to 2009, horizontally-acquired resis-
tance had not been reported. If cross-selection from
chloroquine results in antibacterial resistance more
globally, then 1) FQREC should be commonplace in
equatorial Africa, which has seen the greatest pressure
from chloroquine, and 2) FQREC would have evolved
before the introduction of quinolone antibacterials. We
report quinolone susceptibility trends among commensal
E. coli isolated from apparently healthy undergraduate
students over three decades and antimicrobial use at the
University health center over that period. Quinolone
resistance emerged within the last decade and was coin-
cident with the introduction of the fluoroquinolone
ciprofloxacin.
2. Methods
2.1. Bacterial isolates
Permission to conduct this study was provided by the
Institutional Review Board of Obafemi Awolowo Univer-
sity, Ile-Ife, Nigeria. E. coli isolates were recovered from
stool specimens collected from apparently healthy
undergraduates at Obafemi Awolowo University as
described previously [21]. Data from isolates collected in
1986-1998 has been described previously. For this study,
we collected and processed specimens in 2005 and 2009
using identical protocols. All volunteers submitting a
stool specimen gave informed consent. The identity of
colonies with a typical E. coli morphology on MacCon-
key agar was confirmed by biochemical testing. Colonies
from the same specimen with identical biochemical and
susceptibility profiles were treated as identical isolates.
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Each strain was tested for susceptibility to eight antimi-
crobials using the Clinical and Laboratory Standards
I n s t i t u t e( C L S I ,f o r m e r l yN C C L S )d i s cd i f f u s i o nm e t h o d
[22]. Discs used contained ampicillin (10 μg), streptomy-
cin (10 μg), trimethoprim (5 μg), tetracycline (30 μg),
nalidixic acid (30 μg), chloramphenicol (30 μg), ciproflox-
acin (5 μg) and sulphonamide (300 μg) (Oxoid/Remel)
and E. coli ATCC 35218 was used as control strain. Inhi-
bition zone diameters were interpreted in accordance
with CLSI guidelines using WHONET software version
5.3 [23]. Minimum inhibitory concentrations (MICs) to
nalidixic acid were measured using the agar dilution
technique on Mueller-Hinton agar as recommended by
the CLSI and using E. coli ATCC 35218 as control [24].
MICs to nalidixic acid were also measured in the pre-
sence of efflux pump inhibitor phe-arg b-naphthylamide.
2.3. Mutational analysis of the quinolone-resistance
determining regions of gyrA and parC
DNA was extracted from each quinolone-resistant iso-
late, using the Promega Wizard genomic extraction kit.
The quinolone-resistance determining regions of the
gyrA and parC genes were amplified from DNA tem-
plates by PCR using Platinum PCR supermix (Invitro-
gen) and the primer pairs listed in Additional file 1,
Table S1. PCR reactions began with a two-minute hot
start at 94°C followed by 30 cycles of 94°C for 30s,
annealing temperature, 30s and 72°C for 30s. gyrA
amplifications were annealed at 58°C and parC reactions
were annealed at 52°C. E. coli K-12 MG1655 [25] was
used as a control. Amplicons were sequenced on both
strands and predicted peptide sequences were compared
to the corresponding gene from the MG1655 genome
[25] by pair-wise FASTA alignments.
2.4. Identification of horizontally-acquired quinolone-
resistance genes
qnrA, qnrB,a n dqnrS were identified with PCR using
the primer pairs published by Wu et al [26]. The pri-
mers of Liu et al [27] were used to screen for the qepA
gene (Additional file 1, Table S1). Amplicons were
sequence-verified.
2.5. Organic solvent tolerance
The qualitative organic solvent tolerance test used by
Wang et al [18] was employed. Briefly 10
3-10
4 mid-log
phase bacteria were spotted onto glass plates of LB agar
and overlaid with hexane, cyclohexane or a 1:1 [vol:vol]
mixtures of these solvents. Strains were scored as produ-
cing no growth under any solvent (-), growth under all
solvents (+++) or some solvents (+ or ++). Pseudomonas
aeruginosa strain PA14 and E. coli MG1655 were used as
positive and negative controls respectively.
2.6. Determination of transcript levels by quantitative
real-time PCR
Total RNA was extracted from late log-phase cultures
using the Qiagen RNeasy Protect bacterial minikit. Fol-
lowing reverse transcription using the Taqman Reverse
Transcription Reagents and random hexamers (Applied
Biosystems), quantitative real-time PCR with SYBR
green was performed using primer pairs specific for
genes of the components of the efflux pumps or efflux
pump regulators using primers of Nishino et al. [28]
and Bohnert et al. [29] (Additional file 2, Table S2). The
reactions were run on the StepOne Real-time PCR sys-
tem and performed according to manufacturers recom-
mendations (Applied Biosystems). Gene expression
levels were compared to the control strain MG1655, and
analyzed using the 2
-ΔΔCt method [30]. The rrsA gene
was used as the normalizing gene. Each reaction was
performed in quadruplicate.
2.7. Flagellin typing
fliC PCR-restriction fragmentl e n g t hp o l y m o r p h i s m
(RFLP) typing was performed as described by Fields et
al [31]. The fliC gene of test E. coli strains was amplified
using the primers F-FLIC1 and R-FLIC2 (Additional file
1, Table S1). Amplicons were digested with RsaIa n d
restriction profiles were discriminated after electrophor-
esis on 2.5% agarose gels.
2.8. Multi-locus sequence typing
PCR primers listed in Additional file 1, Table S1 were
used to amplify gene fragments from the adk, fumC,
gyrB, icd, mdh, purA and recA, as described by Wirth et
al [32]. Amplified DNA products were sequenced from
both ends. Allele assignments were made at the publicly
accessible E. coli MLST database accessible from http://
www.mlst.net/. Phylogenetic inferences about ancestral
allelic profiles and strain interrelatedness were made
using eBURSTv3 at http://eburst.mlst.net/ defining
sequence type (ST) complexes, that is clonal complexes,
based on groups sharing six identical alleles.
2.9. Prescription audit of antimicrobial use
Prescription sheets were obtained with permission from
the Obafemi Awolowo University Ile- Ife, Nigeria for
1984, 1985 and 1986; for 1994, 1995 and 1996 and for
2004, 2005 and 2006. Data from the prescription sheets
was collated into a spreadsheet anonymously and then
the prescription sheets were returned to the University
Health Centre. For each year that was evaluated, 300
prescriptions were randomly selected for each month,
permitting evaluation of 4-8% of the prescriptions that
were actually filled. Prescriptions for all oral and topical
antimicrobials, filled at the institution’sP h a r m a c yw e r e
documented and units of measurement were
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using the AB Consumption Calculator tool [33].
3. Results
3.1. Emergence of fluoroquinolone resistance among
commensal E. coli from south-western Nigeria
Our previous studies which tracked resistance in fecal E.
coli isolates between 1986 and 1998 found uncommon
(0-3.2%) and, in all but one case, low-level resistance to
nalidixic acid and no fluoroquinolone resistance [21].
All but one of the nalidixic acid-resistant isolates identi-
fied before 1998 produced an inhibition zone diameter
of at least 10 mm (Nalidixic acid sensitive strains have
zone diameters > 18 mm. Resistant strains have zone
diameters < 14 mm). Due to repeated power cuts in
Nigeria, that strain archive is lost and none of those iso-
lates are available for analysis. Employing an identical
protocol in 2005 we recovered nalidixic acid non-sus-
ceptible E. coli from 18 (21.7%) volunteers. Four isolates
exhibited high-level nalidixic acid resistance, producing
no inhibition zone and MICs of ≥ 4 μgm l
-1, and one of
these was fluoroquinolone-resistant (Table 1). The
remaining isolates exhibited low-level nalidixic acid
resistance similar to that seen with earlier isolates
reported previously [21]. No 2005 isolate carried hori-
zontally-transmitted qnr or qepA genes but the four
high-level nalidixic acid-resistant strains had mutations
in the quinolone-resistance determining regions (QRDR)
of quinolone target gyrA and the single FQREC isolate
had an S80I substitution in ParC (Table 1).
In 2009, we recovered nalidixic acid-resistant E. coli
from 35 (34.5%) volunteers of which 11 isolates were
fluoroquinolone non-susceptible. Isolates obtained from
nine individuals in 2009 harbored one or more non-
synonymous mutations in gyrA and parC QRDRs and
six isolates from the same year carried the horizontally-
transmitted quinolone-resistance gene qnrS1 [34] (Table
1). Altogether, quinolone-specific mechanisms of resis-
tance were identified in 16 isolates from 15 (17.4%) indi-
viduals in 2009, compared to 4 (4.8%) in 2005 (p < 0.05,
Chitest with Yates correction for small numbers). All
FQREC strains carried two or more QRDR mutations
and/or qnrS1 (Table 1).
3.2. Molecular basis for nalidixic acid resistance in isolates
obtained in 2005, during the transition to
fluoroquinolone resistance
We isolated 21 nalidixic-acid resistant E. coli strains
from 18 volunteers in Nigeria in 2005 and one of these
was resistant to the fluoroquinolone ciprofloxacin. The
majority (17) showed low-level nalidixic acid resistance
and did not have mutations in gyrA or parC,n o rd i d
they carry horizontally-transmitted quinolone resistance
qnr and qepA genes. Most of these isolates showed
undue tolerance to organic solvents, suggesting that
overactive efflux pumps may account for resistance
(Table 2). We measured nalidixic acid MICs by agar
dilution in the absence and presence of the RND-type
efflux pump inhibitor phe-arg b-naphthylamide. As
shown in Table 2 test strains showed an 8-fold or
greater reduction in the concentration of nalidixic acid
needed to inhibit growth in the presence of phe-arg b-
naphthylamide, strongly suggesting a role for up-regu-
lated efflux pumps. To confirm efflux pump upregula-
tion, we used quantitative real-time PCR (qPCR) to
measure transcription of 13 genes representing the
major known efflux systems in E. coli.C o m p a r e dt oE.
coli K-12 strain MG1655, sixteen isolates showed a two-
fold or greater upregulation in transcription of the
outer-membrane extrusion factor gene tolC. Seventeen
of the isolates showed two-fold or greater increases in
transcription of one or more other efflux genes and at
Table 1 Quinolone-specific resistance mechanisms in 2005 and 2009 nalidixic acid-resistant isolates
Number of isolates Nalidixic acid MIC Ciprofloxcin GyrA SNPs ParC SNPs Horizontally-acquired
2005
3 8-32 Sensitive S83L - -
1 1024 Resistant S83L, D87N S80I -
2009
2 256 Sensitive D101G* - -
1 16 Sensitive S83L - -
1 1024 Resistant S83L, D87N - -
4 > 1024 Resistant S83L, D87N S80I -
1 64 Sensitive - S94F* -
1 256 Sensitive - V54I* -
1 32 Resistant - Y74C* qnrS1
5 16-256 Resistant - - qnrS1
*Previously unreported SNP for which there is no evidence of functional contribution to resistance
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Page 4 of 10Table 2 Multilocus sequence types and antimicrobial efflux mechanisms in 2005 quinolone-resistant isolates
QREC
Strain
MLST
ST
ST
Complex
fliC
type
Resistance
Profile
Nalidixic
acid MIC
(μg/ml)
Organic
solvent
tolerance
Nalidixic acid
fold inhibition
with PAbN
Δ
GyrA
Δ
ParC
Transcription
fold change-
tolC
Efflux pump genes
with transcription fold
change ≥ 4
Efflux regulator
genes with
transcription fold
change 2-8
Efflux regulator
genes with
transcription fold
change > 8
01A 10 10 A A NSLTR 32 + 4 S83L - 2.0 emrK - rob
05C 10 10 B NS TR 4 ++ 8 - - 1.0 mdtA - -
23A 10 10 B AC NSLTR 4 ++ 8 - - 2.0 mdtA marA, soxS, beaS,
marR, acrR
-
33A 10 10 B AC NSLTR 4 ++ 8 - - 4.5 acrA, acrD, acrE, bcr,
cusB, emrA, emrD, emrK,
fsr,
marA, soxS, evgA,
marR, acrR
rob, baeS
25A 10 10 D A NSLTR 4 ++ 8 - - 16.8 acrA, acrD, acrE, bcr,
cusB, emrA,emrD, emrK,
fsr, macA, mdfA, mdtA
evgA marA, soxS, rob, beaS,
marR, acrR
40B 10 10 E N 4 +++ 8 - - 1.0 -- -
16A 34 10 E NS 4 +++ 16 - - 4.2 acrA, acrD, acrE, bcr,
cusB, fsr, mdtA
marA, soxS, rob, marR,
acrR
baeS
49A 43 10 F N 4 + 8 S83L - 2.2 -- -
23B 10 10 C C N LTR 4 8 - - 2.2 -- -
31A 494 none C A NSLTR 4 ++ 8 - - 2.2 acrD, acrE, bcr, emrA,
mdtA
baeS -
38C 521 none C NS R 4 ++ 8 - - 4.3 acrA, acrD, acrE, bcr,
cusB, emrA, emrD, fsr,
mdfA, mdtA
marA, soxS, evgA, rob,
marR, acrR
beaS,
22A 452 none C NSLTR 4 + 8 - - 1.1 -- -
31B 452 none C NSLTR 4 - 4 - - 2.5 -- -
33B 504 none K NSLT 1024 +++ 16 S83L - 1.0 -- -
34B 498 467 G NS 4 ++ 8 - - 2.1 - baeS -
32C 503 13 H NSLTR 4 ++ 8 - - 1.0 - baeS -
30A 156 156 I AC NSLTR 4 ++ 16 - - 4.3 acrA, acrD, cusB, emrA,
emrK, mdfA
soxS, baeS -
27A 448 448 J ACPNSLTR 1024 +++ 2 S83L,
D87N
S80I 33.2 acrA, acrD, acrE, bcr,
cusB, emrA, emrD, fsr,
macA, mdfA, mdtA
- marA, soxS, evgA, rob,
beaS, marR, acrR
09C 517 none L AC NSLTR 4 ++ 8 - - 8.6 acrA, acrD, acrE, bcr,
cusB, emrA,emrD, emrK,
fsr, mdfA, mdtA
marA, soxS, evgA, rob,
marR, acrR
beaS
38A 517 none N A NSLTR 4 ++ 8 - - 4.2 acrR, acrD, acre, bcr,
cusB, fsr, mdtA
marA, soxS, evgA, rob,
baeS, marR, acrR
ATCC
25922
ND ND ND - 2 - 8 ND ND 0.4 -- -
NCTC10418 ND ND ND - 2 - 4 ND ND 2.1 -- -
ND: Not Determined
Antimicrobials: A, ampicillin; C, chloramphenicol; P, ciprofloxacin; N, nalidixic acid; S, streptomycin; L, sulfonamides; T, tetracycline; R, trimethoprim
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0least half of the targets were upregulated in most iso-
lates (Table 2). The acrA efflux pump gene and acrR,
encoding the gene’s transcriptional regulator, and their
promoters, were sequenced from five strains but none
contained nucleotide polymorphisms that could account
for increased efflux. We next examined transcription of
six genes encoding regulators of efflux genes, including
acrR, by qPCR and most strains showed upregulated
transcription of one or more of these genes (Table 2).
Of the three E. coli strains we employed as controls,
strains ATCC 25922 and MC4100 produced fold
changes for all genes ranging between 0.5 and 1.4 (com-
pared to K-12 strain MG1655) for the different genes
but we saw a two-fold increase for NCTC 10418 for
nine efflux pump genes but none of the efflux regula-
tors. Twelve of the QREC from Nigeria showed a four-
fold or greater fold change in transcription of at least
one gene encoding an efflux pump component and all
but one of these strains had a two-fold of greater fold
upregulation of one or more regulators. Thus, elevated
efflux is the most likely explanation for low-level resis-
tance seen in most of the 2005 isolates.
MLST of quinolone-resistant E. coli revealed a star-
tling lack of diversity with the 21 strains representing
only 13 sequence types. Nine isolates belonging to
sequence type (ST) complex 10 and seven specifically
belonging to ST 10. ST452 (2 isolates) and its single
locus variant ST521, represented a second frequently
occurring clonal complex and we identified one ST156
strain, which along with ST10 has recently been identi-
fied among quinolone-resistant E. coli in Ghana (Table
2)[35].
3.3. Antimicrobial prescription trends at the University
Health center
As shown in Table 3, prescribing practices at the Health
Center were highly physician-specific in the 1980s but
by 2004-2006, had become more uniform. However,
with the increasing uniformity, we observed an overall
increase in the mean and median number of drugs per
prescription (Table 3). While only one of five physicians
averaged more than four drugs per prescription in 1984-
1986, in 2004-2006, seven of nine physicians were pre-
scribing an average of four drugs or more per patient.
In spite of the very small number of prescribing physi-
cians, this difference approached statistical significance
(p = 0.06 Fishers exact test). Anti-infectives, the most
commonly prescribed medicines at the health center,
represented 49.3% of the drugs listed on prescriptions
between 1984 and 1986, 21.9% in 1994-1996 and 38.7%
in 2004-2006.
In the 1980s, chloroquine accounted for over 96% of
all antimalarials prescribed. Pyrimethamine alone was
prescribed in prophylactic doses only and sulphadoxine-
pyrimethamine, which is more expensive than chloro-
quine but much cheaper than other antimalarials, was
rarely prescribed during the first decade. In the second
decade of the study, this drug combination was pre-
scribed for 5% of patients receiving an antimalarial and
by the 2000s, it was recommended for almost 40% (Fig-
ure 1). With the exception of Artemisinin Combination
Therapies (ACTs), use of which increased considerably
between 2004 and 2006, there were no significant
within-decade differences in prescription rates for each
antimalarial. However, antimalarial prescription choices
changed considerably from one decade to the next. Dis-
counting combinations, the greatest diversity of antima-
larial drugs was prescribed in the middle decade, 1990s
(Figure 1) and may have been prompted by emerging
resistance and the absence of a set antimalarial policy.
Amodiaquine and halofantrine represented a significant
proportion of prescriptions in the 1990s, but by the
2000s, all patients not receiving chloroquine or amodia-
quine received ACTs [36]. A decline in chloroquine pre-
scription from 45.4% to 25.1% occurred in parallel with
ACT roll out. However chloroquine prescription was
never discontinued and it remained the antimalarial of
choice for most patients with clinical malaria through-
out the duration of the study (Figure 1).
Like antimalarial prescription, antibacterial prescrip-
tion altered significantly over the study period (Figure
1). Chloramphenicol and tetracycline, drugs of choice in
the 1980s, were prescribed less in the following decades
as drugs that did not have toxicity concerns became
available and more affordable. Prescription of the ami-
nopenicillins ampicillin and amoxicillin for example
increased eight-fold from between the first and last dec-
ade. As with antimalarials, with the exception of tetracy-
cline, drugs that fell out of favor were never completely
discontinued so that selective pressure from them was
never removed. Ciprofloxacin was the only quionolone
prescribed at the health center and was introduced in
the 2000s, the decade in which E. coli with quinolone-
specific resistance mechanisms were detected.
Table 3 Prescribing patterns of physicians in the
University Health Center
1984-
1986
1994-
1996
2004-2006
Number of prescribing
physicians
71 0 9
Mean ± SD drugs per
prescription
3.1 ± 1.1 3.2 ± 0.5 4.5 ± 0.5
Median (Range for different
physicians) drugs per
prescription
3.1 (1.6-5) 3.25 (2.5-4) 4.71 (3.5-4.9)
Lamikanra et al. BMC Infectious Diseases 2011, 11:312
http://www.biomedcentral.com/1471-2334/11/312
Page 6 of 104. Discussion
This study allowed us to broach the almost untestable
question of population-level selective forces for quino-
lone resistance in bacteria within a malaria-endemic
area. The long duration of resistance monitoring offered
significant advantages in spite of unavoidable limitations.
We deemed it important to replicate the methodology
of earlier years, which means that we only examined a
small sample of the commensal E. coli population car-
ried by each volunteer. Other limitations of this study
include the fact that our prescription audit did not sam-
ple the complete catalogue of selective pressure for
resistance. It is unlikely that patients who receive free
medications at the health center would have chosen to
purchase their prescriptions elsewhere, however, we can-
not rule out the possibility that patients may have pur-
chased other medicines to augment, or replace, those
offered at the health center. Prescriptions for parenteral
drugs are handled differently and records are not
retained long-term at the center and therefore inject-
ables were not evaluated, even though it is well known
that many commonly used antimicrobials are adminis-
tered intramuscularly in Nigeria [37].
The quinolone resistance rates and their association
with access to quinolones that we have recorded in this
study compare with those from reports from other parts
of Nigeria and West Africa, and all support the hypoth-
esis that fluoroquinolone introduction immediately pre-
cedes the evolution of FQREC [38-42]. However, it is
difficult to draw even cautious conclusions across multi-
ple studies and or from anecdotes. Therefore, in spite of
the aforementioned limitations, the present study pro-
vides coherent evidence to support the hypothesis
because it tracks resistance and use in a select area
Figure 1 Antibacterial and Antimalarial prescription at the University Health Center. Daily defined doses (DDDs) of antimalarials (A) and
antibacterials (B) dispensed from the Health center pharmacy in the 1980s, 1990s and 2000s.
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Page 7 of 10using simple but reproducible methodology. Our data
show that quinolone resistance emerged in commensal
E. coli after the 1990s in Ile-Ife, Nigeria, and that our
2005 isolate collection, largely but not entirely com-
prised of low-level resistors, appears to have been pro-
cured at a critical juncture-shortly after the evolution of
resistance. By 2009, 16 (46%) of quinolone-resistant iso-
lates showed high-level quinolone resistance, and resis-
tance to the fluoroquinolones, attributable to quinolone-
specific resistance mechanisms that have commonly
been reported in other studies. Resistance-conferring
mutations in gyrA and parC were the most commonly
recorded of these resistance mechanisms. When hori-
zontally-transmitted resistance evolved, qnrS1 was the
most frequently detected transmissible allele among
commensal E. coli from Vietnam and Ghana, where like
Nigeria antimicrobials are freely available and fecal-oral
transmission of bacteria is common [35,43]. Altogether,
we observed rapid, stepwise evolution of FQREC
between 2005 and 2009, from a very low baseline.
The predominance of ST10 among 2005 quinolone
resistant isolates may be due to the overall predomi-
nance of ECOR phylogenetic group A strains in West
Africa [44]. However, we have recently shown that this
lineage is overrepresented among quinolone-resistant
strains, as compared to sensitive strains in Ghana [35].
We performed in-depth analyses of the 2005 isolates
from this study to get a sense of how resistance might
have evolved and our data suggest that strains with
overactive efflux may have been the predecessors of
strains exhibiting quinolone-specific resistance mechan-
isms. The differences in efflux phenotypes, efflux genes
transcription profiles and flagellin types among most of
the strains belonging to the same ST suggest that the
low-level resistance we detect is not primarily due to
expansion of recently derived clones. Instead, the data
appear to suggest that elevated efflux is more likely to
be seen in specific lineages, likely those with overactive
efflux pumps. This in turn points to the idea that cer-
tain lineages may be primed to evolve more stable, less
costly resistance. Horizontally-transmitted qnr genes,
including qnrS1 identified in this study have recently
been implicated in providing low-level quinolone resis-
tance that could provide strains with the opportunity to
acquire subsequent mutations in quinolone targets and
therefore higher-level stabler e s i s t a n c e[ 4 5 ] .I ti st h e r e -
fore worrisome that qnrS1 can now be commonly
detected among E. coli commensals in Nigeria. More
studies are needed to improve our understanding of the
evolution and dissemination of quinolone resistance. We
suggest that on-going and proposed studies tracking
resistance across Africa include a focus on quinolone
resistance at genetic as well as phenotypic levels and
that more work is done to elucidate the genetic context
of successful horizontally transmitted quinolone resis-
tance genes as they appear in African countries, similar
to work that has been done in Vietnam [43].
Rampant non-prescription use, informal supply chains
and a dearth of archival records make it challenging to
quantify drug use in Nigeria. However, the health center
at the University where we tracked resistance offers stu-
dents and staff free health care and archives dispensed
prescriptions. This long-term study was thus conducted
in a setting that provided ther a r eo p p o r t u n i t yt or e t r o -
spectively study antimicrobial prescription patterns in an
equatorial Africa locality where resistance was also
tracked. We find that chloroquine prescription was inor-
dinately high in the 1980s with 97% of patients visiting
the health center receiving this drug. Chloroquine pre-
scription declined steadily thereafter but never dropped
below 500 daily-defined doses, with 25% of patients
receiving this drug in 2006 (Figure 2). In contrast to the
earlier report from Guyana [4], we do not find evidence
of selection for FQREC from heavy and long-running
chloroquine use in this setting. By contrast, quinolone
antibacterials were never used before the 2000s and
introduction of ciprofloxacin is temporally associated
with evolution, and rising rates, of FQREC carriage by
campus undergraduates. The significance of our findings
cannot be over-emphasized since current efforts to ‘bring
back’ chloroquine, an extremely effective and cheap anti-
malalarial, would be de-prioritized if there were adverse
consequences on resistance in other organisms.
The number of drugs prescribed per patient and the
common use of antimicrobial drugs we documented
compare with studies performed elsewhere in Nigeria
for the respective periods [46,47]. Overall antimicrobial
Figure 2 Proportion of Escherichia coli isolates from students in
Ile-Ife, Nigeria that were quinolone resistant (1986-2009, right
axis) with grey portions of the bars indicating strains resistant
to nalidixic acid alone and black shading representing strains
resistant to nalixic acid and the fluoroquinolone ciprofloxacin.
Daily defined doses of chloroquine (diamonds) and ciprofloxacin
(circles) dispensed from the University Health center pharmacy in
1984-86, 1994-96 and 2004-06 are plotted from the left axis.
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Page 8 of 10use was characterized by heavy dependence on three
drug classes or less and a shift in favored drug cate-
gories from one decade to another, without withdrawal
of earlier favorites. This drug use pattern, typified by the
antimalarial chloroquine, favors the emergence of stable
resistance [40,48,49].
Quinolones are drugs of last resort that are increasingly
employed in Nigeria and other African countries to man-
age common bacterial infections. In the face of high and
rising resistance to more affordable antimicrobials and
the unavailability of newer, patent protected antibacter-
ials, there is currently no real alternative to their use in
West Africa. Evolution of resistance to the quinolones
among E. coli has important clinical implications because
resistance patterns in commensals typically mirror those
seen in pathogens exposed to similar selection. A recent
report from neighboring Cameroon suggests that quino-
lone resistance has emerged among Salmonella enterica
serovar Typhi there [50] and we have reported quinolone
resistance in epidemic Vibrio cholerae from Ghana [51].
Conclusion
This study charts the appearance of quinolone-resistant
E. coli in a Nigerian malaria endemic community, which
has seen heavy and long-term use of chloroquine. The
study demonstrates that quinolone resistance was not
temporally associated with chlrooquine use but appeared
shortly after fluoroquinolone introduction. The diversity
of quinolone-specific resistance mechanisms that
emerged following ciprofloxacin introduction points to
an urgent need for therapeutic alternatives and resis-
tance containment. Our findings suggest that the useful
lifespan for newly introduced antimicrobials that have
been used extensively elsewhere can be short. High
prices of patent-protected drugs delay their introduction
to developing countries and strategies for ensuring early
but controlled access to novel antimicrobials may be
necessary to ensure medium- to long-term efficacy in
resource-limited settings.
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